The APOBEC1 paradigm for mammalian cytidine deaminases that edit DNA and RNA

DNA and RNA Modification Enzymes: Structure, Mechanism, Function and Evolution

Volumn , Issue , 2009, Pages 181-202

  Smith, Harold C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955671410     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (257)

1. Anant S, Yu H, Davidson NO. Evolutionary origins of the mammalian apolipoprotcinB RNA editing enzyme, apobec-1: structural homology inferred from analysis of a cloned chicken small intestinal cytidine deaminase. Biol Chem 1998; 379:1075 18081.
2. Nagahara H, Vocero-Akbani AM, Snyder EL et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kipl induces cell migration. Nat Med 1998; 4:1449-1452.
3. Navaratnam N, Bhattacharya S, Fujino T et al. Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site. Cell 1995; 81:187-195.
4. Navaratnam N, Fujino T, Bayliss J et al. Escherichia coli cytidine deaminase provides a molecular model for ApoB RNA editing and a mechanism for RNA substrate recognition. J Mol Biol 1998; 275(4):695-714.
5. MacElrcvcy CA, Wedekind JE. Chemistry, phylogeny and three-dimensional structure of the APOBEC protein family. In RNA and DNA Editing: Molecular mechanisms and their integration inot biological systems. (H. Smith, ed) Hoboken, NJ: Wiley and Sons 2008; 16:369-420.
6. MacGinnitie AJ, Anant S, Davidson NO. Mutagenesis of APOBEC-1, the catalytic subunit of the mammalian apolipoprotcin B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA-binding and RNA editing activity. J Biol Chem 1995; 270:14768-14775.
7. Yamanaka S, Poksay KS, Balestra ME et al Cloning and mutagenesis of the rabbit ApoB mRNA editing protein. A zinc motif is essential for catalytic activity and noncatalytic auxiliary focror(s) of the editing complex are widely distributed. J Biol Chem 1994; 269:21725-21734.
8. Barnes C, Smith HC. Apolipoprotein B mRNA editing in vitro is a zinc-dependent process. Biochem Biophys Res Commun 1993; 197:1410-1414.
9. Johnson DF, Poksay KS, Innerarity TL. The mechanism for apo-B mRNA editing is deamination. Biochem Biophys Res Commun 1993; 195:1204-1210.
10. Navaratnam N, Morrison JR, Bhattacharya S et al The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J Biol Chem 1993; 268:20709-20712.
11. Smith AA, Carlow DC, Wolfenden R et al. Mutations affecting transition-state stabilization by residues coordinating zinc at the active site of cytidine deaminase. Biochemistry 1994; 33:6468-6474.
12. Jatmuz A, Chester A, Bayliss J et al. An Anthropoid-specific locus of orphan C to U RNA-Editing enzymes on chromosome 22. Genomics 2002; 79:285-296.
13. Mian IS, Moser MJ, Holley WK et al. Statistical modelling and phylogenetic analysis of a deaminase domain. J Comput Biol 1998; 5:57-72.
14. Wedekind JE, Dance GS, Sowden MP et al Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet 2003; 19:207-216.
15. Maas S, Rich A, Nishikura K. A-to-I RNA editing: recent news and residual mysteries. J Biol Chem2003; 278:1391-1394.
16. Keegan LP, Leroy A, Sproul D et al. Adenosine deaminases acting on RNA (ADARs): RNA-editing enzymes. Genome Biol 2004; 5:209.
17. Reenan RA. The RNA world meets behavior: A—>I pre-mRNA editing in animals. Trends Genet 2001; 17:53-56.
18. Smith HC. Editing informational content of expressed DNA sequences and their transcripts. In the implicit genome 2006; (LH Caporale, ed) NY, NY: Oxford University Press 2006; 14:248-265
19. Smith HC, Wedekind JE, Xic K et al Mammaliam C to U editing. Topics in current genetics. (H Grosjean, ed) Germany: Springer-Verlag 2005; 12:365-400.
20. Sawyer SL, Emerman M, Malik HS. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2004; 2:E275.
21. Conticello SG, Thomas CJ, Petersen-Mahrt SK et al. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol 2005; 22:367-377.
22. Liao W, Hong SH, Chan BH et al APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochem Biophys Res Commun 1999; 260:398-404.
23. Rogozin IB, Basu MK, Jordan IK et al APOBEC4, a new member of the AID/APOBEC fitmdy of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 2005; 4:1281-1285.
24. MacDuff DA, Offer SM, Demorest ZL et al. Antibody gene diversification by AID-Catalyzed DNA Editing. In: RNA and DNA Editing: Molecular mechanisms and their integration into biological systems. (HC, Smith, ed) John Wiley and Sons 2008; 2:31-70.
25. Peled JU, Kuang FL, Iglesias-Ussel MD et al. The biochemistry of somatic hypermutation. Annu Rev Immunol 2008; 26:481-511.
26. Stavnczer J, Guikcma JE, Schrader CE. Mechanism and regulation of class switch recombination. Annu Rev Immunol 2008; 26:261-292.
27. Fugmann SD, Schatz DG. Immunology. One AID to unite them all Science 2002; 295:1244-1245.
28. Honjo T, Muramatsu M, Fagarasan S. AID: how does it aid antibody diversity? Immunity 2004; 20:659-668.
29. Ichikawa HT, Sowden MP, Torelli AT et al Structural phylogenetic analysis of activation-induced deaminase function. J Immunol 2006; 177:355-361.
30. Zhao Y, Pan-Hammarstrôm Q, Zhao Z et al. Identification of the activation-induced cytidine deaminase gene from zebrafish: an evolutionary analysis. Dev Comp Immunol 2005; 29:61-71.
31. Barreto VM, Pan-Hammaistrom Q, Zhao Y et al. AID from bony fish catalyzes class switch recombination. J Exp Med 2005; 202:733-738.
32. Hinds-Frey KR, Nishikata H, Litman RT et al Somatic variation precedes extensive diversification of gcrmlinc sequences and combinatorial joining in the evolution of immunoglobulin heavy chain diversity. J Exp Med 1993; 178:815-824.
33. Muramatsu M, Kinoshita K, Fagarasan S et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102:553-563.
34. Rcvy P, Muto T, Levy Y et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hypcr-IgM syndrome (HIGM2). Cell 2000; 102:565-575.
35. Martin A, Bardwcll PD, Woo CJ et al Activation-induced cytidinc deaminase turns on somatic hypermutation in hybridomas. Nature 2002; 415:802-806.
36. Okazaki IM, Kinoshita K, Muramatsu M et al The AID enzyme induces class switch recombination in fibroblasts. Nature 2002; 416:340-345
37. Arakawa H, Saribasak H, Buerstedde JM. Activation-induced cytidine deaminase initiates immunoglobulin gene conversion and hypermutation by a common intermediate. PLoS Biol 2004; 2:E179.
38. Yu K, Roy D, Bayramyan M et al Fine-structure analysis of activation-induced deaminase accessibility to class switch region R-loops. Mol Cell Biol 2005; 25:1730-1736.
39. Larson ED, Maizels N. Transcription-coupled mutagenesis by the DNA deaminase AID. Genome Biol 2004; 5:211.
40. Nambu Y, Sugai M, Gonda H et al. Transcription-coupled events associating with immunoglobulin switch region chromatin. Science 2003; 302:2137-2140.
41. Chaudhuri J, Tian M, Khuong C et al Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 2003; 422:726-730.
42. Rada C, Williams GT, Nilsen H et al. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-dcficicnt mice. Curr Biol 2002; 12:1748-1755.
43. Imai K, Slupphaug G, Lee WI et al Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol 2003; 4:1023-1028.
44. Bross L, Muramatsu M, Kinoshita K et al. DNA Double-Strand Breaks: Prior to but not Sufficient in Targeting Hypermutation. J Exp Med 2002; 195:1187-1192.
45. Papavasiliou FN, Schatz DG. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. Nature 2000; 408:216-221.
46. Brar SS, Watson M, Diaz M. Activation-induced cytosine deaminase (AID) is actively exported out of the nucleus but retained by the induction of DNA breaks. J Biol Chem 2004; 279:26395-26401.
47. Barreto V, Reina-San-Martin B, Ramiro AR et al C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol Cell 2003; 12:501-508.
48. Shinkura R, Ito S, Begum NA et al. Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat Immunol 2004; 5:707-712.
49. Chiu YL, Greene WC. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 2008; 26:317-353.
50. Strebel K, Khan MA. APOBEC3G cncapsidation into HIV-1 virions: which RNA is it? Retrovirology2008; 5:55.
51. Hakata Y, Landau NR. Reversed functional organization of mouse and human apobec3 cytidine deaminase domains. J Biol Chem 2006; 281:36624-36631.
52. Jonsson SR, Hache G, Stenglein MD et al. Evolutionarily conserved and nonconserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res 2006; 34:5683-5694.
53. OhAinle M, Kerns JA, Malik HS et al. Adaptive evolution and antiviral activity of the conserved mammalian cytidinc deaminase APOBEC3H. J Virol 2006; 80:3853-3862.
54. Zhang J, Webb DM. Rapid evolution of primate antiviral enzyme APOBEC3G. Hum Mol Genet 2004; 13:1785-1791.
55. Kinomoto M, Kanno T, Shimura M et al. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res 2007; 35:2955-2964.
56. Turelli P, Vianin S, Trono D. The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J Biol Chem 2004; 279:43371-43373.
57. Muckenfuss H, Hamdorf M, Held U et al. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem 2006; 281:22161-22172.
58. Bogerd HP, Wicgand HL, Doehle BP et al. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 2006; 34:89-95.
59. Jonsson SR, LaRuc RS, Stenglein MD et al. The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS ONE 2007; 2:e893.
60. Esnault C, Heidmann O, Delebecque F et al APOBEC3G cytidinc deaminase inhibits retrotransposition of endogenous retroviruses. Nature 2005; 433(7024):430-433.
61. Ortiz M, Bleiber G, Martinez R et al. Patterns of evolution of host proteins involved in retroviral pathogenesis. Retrovirology 2006; 3:11.
62. Kidd JM, Newman TL, Tuzun E et al. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 2007; 3:e63.
63. Sheehy AM, Gaddis NC, Choi JD et al Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646-650.
64. von Schwedler U, Song J, Aiken C et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993; 67:4945-4955.
65. Simon JH, Malim MH. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nudeoprotein complexes. J Virol 1996; 70:5297-5305.
66. Madani N, Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol 1998; 72:10251-10255.
67. Simon JH, Gaddis NC, Fouchier RA et al Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 1998; 4:1397-1400.
68. Harris RS, Bishop KN, Sheehy AM et al DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113:803-809.
69. Yu Q, Konig R, Pillai S et al Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 2004; 11:435-442.
70. Zhang H, Yang B, Pomerantz RJ et al The cytidinc deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424:94-98.
71. Branstcitter R, Pham P, Scharff MD et al. Activation-induced cytidine deaminase deaminates deoxycy-tidine on single-stranded DNA but requires the action of RNase. Proceedings of the National Academy of Sciences USA 2003; 100:4102-4107.
72. Chelico L, Pham P, Calabrese P et al. APOBEC3G DNA deaminase acts processively 3' → 5' on single-stranded DNA. Nat Struct Mol Biol 2006; 13:392-399.
73. Suspenc R, Rusniok C, Vartanian JP et al Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 2006; 34:4677-4684.
74. Janini M, Rogers M, Bin DR et al. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T-cells. J Virol 2001; 75:7973-7986.
75. Pace C, Keller J, Nolan D et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 2006; 80:9259-9269.
76. Simon V, Zennou V, Murray D et al Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 2005; 1:e6.
77. Beale RC, Petersen-Mahrt SK, Watt IN et al Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol 2004; 337:585-596.
78. Bishop KN, Holmes RK, Sheehy AM et al Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004; 14:1392-1396.
79. Harris RS, Petersen-Mahrt SK, Neuberger MS. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 2002; 10:1247-1253.
80. Petersen-Mahrt SK, Neuberger MS. In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1). J Biol Chem 2003; 278:19583-19586.
81. Han Y, Wang X, Dang Y et al APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathog 2008; 4:e1000095.
82. Hache G, Liddament MT, Harris RS. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-tcrminal DNA cytosine deaminase domain. J Biol Chem 2005; 280:10920-10924.
83. Iwatani Y, Takeuchi H, Strebel K et al Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol 2006; 80:5992-6002.
84. Navarro F, Bollman B, Chen H et al. Complementary function of the two catalytic domains of APOBEC3G. Virology 2005; 333:374-386.
85. Shindo K, Takaori-Kondo A, Kobayashi M et al. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J Biol Chem 2003; 278:44412-44416.
86. Bogeid HP, Cullen BR. Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 2008; 14:1228-1236.
87. Svarovskaia ES, Xu H, Mbisa JL et al Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 2004; 279:35822-35828.
88. Bishop KN, Holmes RK, Malim MH. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 2006; 80:8450-8458.
89. Newman EN, Holmes RK, Craig HM et al Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 2005; 15:166-170.
90. Guo F, Cen S, Niu M et al Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol 2006; 80:11710-11722.
91. Gaddis NC, Chcrtova E, Shechy AM et al. Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol 2003; 77:5810-5820.
92. Guo F, Cen S, Niu M et al. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol 2007; 81:11322-11331.
93. Schumacher AJ, Hache G, Macduff DA et al. The DNA deaminase activity of human APOBEC3G is required for Tyl, MusD and human immunodeficiency virus type 1 restriction. J Virol 2008; 82:2652-2660.
94. Noguchi C., Ishino H, Tsuge M et al. G to A hypermutation of hepatitis B virus. Hepatology 2005; 41:626-633.
95. Rosier C, Kock J, Kann M et al. APOBEC-mediated interference with hepadnavirus production. Hepatology 2005; 42:301-309.
96. Suspene R, Guetard D, Henry M et al. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sei USA 2005; 102:8321-8326.
97. Turelli P, Mangeat B, Jost S et al. Inhibition of hepatitis B virus replication by APOBEC3G. Science2004; 303:1829.
98. Esnault C, Millet J, Schwartz O et al. Dual inhibitory effects of APOBEC family proteins on retrotrans-position of mammalian endogenous retroviruses. Nucleic Acids Res 2006; 34:1522-1531.
99. Stenglein MD, Harris RS. APOBEC3B and APOBEC3F inhibit LI retrotransposition by a DNA deamination-independent mechanism. J Biol Chem 2006; 281:16837-16841.
100. Huhne AE, Bogerd HP, Cullen BR et al. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 2007; 390:199-205.
101. Chiu YL, Witkowska HE, Hall SC et al. High-molecular-mass APOBEC3G complexes restriet alu retrotransposition. Proc Natl Acad Sei USA 2006; 103:15588-15593.
102. Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J Biol Chem 1992; 267:25621-25624.
103. Farese RV Jr, Ruland SL, Flynn LM et al. Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. Proc Natl Acad Sei USA 1995; 92:1774-1778.
104. Olofsson SO, Wiklund O, Boren J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vase Health Risk Manag2007; 3:491-502.
105. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004; 109(23 Suppl 1):III2-7.
106. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology 2007; 132:2181-2190.
107. Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr Opin Lipidol 2007; 18:633-637.
108. Chen SH, Habib G, Yang CY et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ- specific in-frame stop codon. Science 1987; 238:363-366.
109. Powell LM, Wallis SC, Pease RJ et al. A novel form of tissue-specific RNA processing produces apolipoprotein- B48 in intestine. Cell 1987; 50:831-840.
110. Backus JW, Eagleton MJ, Harris SG et al Quantitation of endogenous liver apolipoprotein B mRNA editing. Biochem Biophys Res Commun 1990; 170:513-518.
111. Greeve J, Altkemper I, Dieterich JH et al. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB- containing plasma lipoproteins. J Lipid Res 1993; 34:1367-1383.
112. Greeve J, Axelos D, Welker S et al. Distinct promoters induce APOBEC-1 expression in rat liver and intestine. Arterioscler Thromb Vase Biol 1998; 18:1079-1092.
113. Ding EL, Malik VS. Convergence of obesity and high glycémie diet on compounding diabetes and cardiovascular risks in modernizing China: An emerging public health dilemma. Global Health 2008; 4:4.
114. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006; 12:62-66.
115. Teng B, Burant CF, Davidson NO. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 1993; 260:1816-1819.
116. Smith HC. Measuring editing activity and identifying cytidine-to-uridine mRNA editing factors in cells and biochemical isolates. Methods Enzymol 2007; 424:389-416.
117. Driscoll DM, Wynne JK, Wallis SC et al. An in vitro system for the editing of apolipoprotein B mRNA. Cell 1989; 58:519-525.
118. Teng B, Davidson NO. Evolution of intestinal apolipoprotein B mRNA editing. Chicken apolipoprotein B mRNA is not edited, but chicken enterocytes contain in vitro editing enhancement factor(s). J Biol Chem 1992; 267:21265-21272.
119. Hirano K, Young SG, Farcsc RV Jr et al Targeted disruption of the mouse apobec-1 gene abolishes apoli-poprotein B mRNA editing and eliminates apolipoprotein B-48. J Biol Chem 1996; 271:9887-9890.
120. Xic Y, Nassir F, Luo J et al. Intestinal lipoprotein assembly in apobcc-1-/- mice reveals subtle alterations in triglyceride secretion coupled with a shift to larger lipoproteins. Am J Physiol Gastrointest Liver Physiol 2003; 285:G735-746.
121. Giannoni F, Bonen DK, Funahashi T et al Complementation of apolipoprotein B mRNA editing by human liver accompanied by secretion of apolipoprotein B48. J Biol Chem 1994; 269:5932-5936.
122. Hughs SD, Rouy D, Nararatnam N et al. Gene transfer of cytidinc deaminase APOBEC-1 lowers lipoprotein(a) in transgenic mice and induces apolipoprotein B mRNA editing in rabbits. Hum Gene Thcr 1996; 7:39-9.
123. Kozarsky KF, Bone DK, Giannoni F et al Hepatic expression of the catalytic subunit of the apolipo-protein B mRNA editing enzyme ameliorates hypercholesterolemia in LDL receptor-deficient rabbits. Hum Gene Therapy 1996; 7:943-957.
124. Qian X, Balestra ME, Yamanaka S et al Low expression of the apolipoprotein B mRNA editing transgene in mice reduces LDL but does not cause liver dysplasia or tumors. Artcriosc. Thromb. Vase Biol 1998; 18:1013-1020.
125. Teng B-Blumenthal S, Forte T et al. Adenovirus-mediated gene transfer of rat apolipoprotein B mRNA editing protein in mice virtually eliminates apolipoprotein B-100 and normal low density lipoprotein production. J Biol Chem 1994; 269:29395-29404.
126. Backus JW, Smith HC. Three distinct RNA sequence elements are required for efficient apolipoprotein B (apoB) RNA editing in vitro. Nucleic Acids Res 1992; 20:6007-6014.
127. Backus JW, Smith HC. Specific 3' sequences flanking a minimal apolipoprotein B (apoB) mRNA editing cassette* are critical for efficient editing in vitro. Biochim Biophys Acta 1994; 1217:65-73.
128. Shah RR, Knott TJ, Legros JE et al Sequence requirements for the editing of apolipoprotein B mRNA. J Biol Chem 1991; 266:16301-16304.
129. Smith HC, Gott JM, Hanson MR. A guide to RNA editing. RNA 1997; 3(10):1105-1123.
130. Backus JW, Smith HC. Apolipoprotein B mRNA sequences 3' of the editing site are necessary and sufficient for editing and editosome assembly. Nucleic Acids Research 1991; 19:6781-6786.
131. Driscoll DM, Lakhe-Reddy S, Oleksa LM et al Induction of RNA editing at heterologous sites by sequences in apolipoprotein B mRNA. Mol Cell Biol 1993; 13:7288-7294.
132. Cappione AJ, French BL, Skuse GR. A potential role for NF1 mRNA editing in the pathogenesis of NF1 tumors. Am J Hum Genet 1997; 60:305-312.
133. Mukhopadhyay D, Anant S, Lee RM et al C→U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-cditing enzyme. Am J Hum Genet 2002; 70:38-50.
134. Sowden M, Hamm JK, Spinelli S et al Determinants involved in regulating the proportion of edited apolipoprotein B RNAs. RNA 1996; 2:274-288.
135. Sowden MP, Smith HC. Commitment of apolipoprotein B RNA to the splicing pathway regulates cytidine-to-uridine editing-site utilization. Biochem J 2001; 359(Pt 3):697-705.
136. Yang Y, Sowden MP, Smith HC. Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1. J Biol Chem 2000; 275:22663-22669.
137. Anant S, MacGinnitie AJ, Davidson NO. Apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein. J Biol Chem 1995; 270:14762-14767.
138. Chester A, Wcinrcb V, Carter CW Jr et al. Optimization of apolipoprotein B mRNA editing by APOBEC1 apoenzyme and the role of its auxiliary factor, ACF. RNA 2004; 10:1399-1411.
139. Wedekind JE, Gillilan R, Janda A et al Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J Biol Chem 2006; 281:38122-38126.
140. Opi S, Takeuchi H, Kao S et al Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol 2006; 80:4673-4682.
141. Shen HM, Ratnam S, Storb U. Targeting of the activation-induced cytosine deaminase is strongly influenced by the sequence and structure of the targeted DNA. Mol Cell Biol 2005; 25:10815-10821.
142. Yu K, Huang FT, Licbcr MR. DNA substrate length and surrounding sequence affect the activation induced deaminase activity at cytidine. J Biol Chem 2004; 279:6496-6500.
143. Maris C, Masse J, Chester A et al NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor. RNA 2005; 11:173-186.
144. Harris SG, Sabio I, Mayer E et al. Extract-specific heterogeneity in high-order complexes containing apolipoprotein B mRNA editing activity and RNA-binding proteins. J Biol Chem 1993; 268:7382-7392.
145. Smith HC, Kuo SR, Backus JW et al. In vitro apolipoprotein B mRNA editing: identification of a 27S editing complex. Proc Natl Acad Sci USA 1991; 88:1489-1493.
146. Mehta A., Kinter MT, Sherman NE et al. Molecular cloning of apobec-1 complementation factor, a novel RNA- binding protein involved in the editing of apolipoprotein B mRNA. Mol Cell Biol 2000; 20:1846-1854.
147. Navaramam N, Shah R, Patel D et al. Apolipoprotein B mRNA editing is associated with UV crosslinking of proteins to the editing site. Proc Natl Acad Sci USA 1993; 90:222-226.
148. Smith HC. Analysis of protein complexes assembled on apolipoprotein B mRNA for mooring sequence-dependent RNA editing. Methods 1998; 15(l):27-39.
149. Blanc V, Henderson JO, Newberry EP et al. Targeted deletion of the murine apobec-1 complementation factor (acf) gene results in embryonic lethality. Mol Cell Biol 2005; 25:7260-7269.
150. Dance GSC, Sowdcn MP, Cartegni L et al. Two proteins essential for apolipoprotein B mRNA editing are expressed from a single gene through alternative splicing. J Biol Chem 2002; 277:12703-12709.
151. Lellek H, Kirsten R, Diehl I et al. Purification and molecular cloning of a novel essential component of the apolipoprotein B mRNA editing enzyme-complex. J Biol Chem 2000; 275:19848-19856.
152. Sowdcn MP, Lehmann DM, Lin X et al Identification of novel alternative splice variants of APOBEC-1 complementation factor with different capacities to support apolipoprotein B mRNA editing. J Biol Chem 2004; 279:197-206.
153. Dance GS, Sowdcn MP, Cartegni L et al Two proteins essential for apolipoprotein B mRNA editing are expressed from a single gene through alternative splicing. J Biol Chem 2002; 277:12703-12709.
154. Blanc V, N.O.D. Biological Implications and Broader-Range Functions for APOBEC-1 and APOBEC-1 Complementation Factor (ACF). In: RNA and DNA Editing: Molecular Mechanism and Their Integration into Biological Systems. (HC Smith, ed). Hoboken, NJ: John Wiley and Sons Inc 2008; 10:203-230.
155. Yang Y, Kovalski K, Smith HC. Partial characterization of the auxiliary factors involved in apolipoprotein B mRNA editing through APOBEC-1 affinity chromatography. J Biol Chem 1997; 272:27700-27706.
156. Anant S, Henderson JO, Mukhopadhyay D et al. Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. J Biol Chem 2001; 276:47338-47351.
157. Blanc V, Navaratnam N, Henderson JO et al. Identification of GRY-RBP as an apolipoprotein B RNA-binding protein that interacts with both apobec-1 and apobec-1 complementation factor to modulate C to U editing. J Biol Chem 2001; 276:10272-10283.
158. Lau PP, Zhu HJ, Nakamuta M et al. Cloning of an Apobec-1-binding protein that also interacts with apolipoprotein B mRNA and evidence for its involvement in RNA editing. J Biol Chem 1997; 272:1452-1455.
159. Sowden MP, Ballatoli N, Jensen KL et al The editosome for cytidine to uridine mRNA editing has a native complexity of 27S: identification of intracellular domains containing active and inactive editing factors. J Cell Sci 2002; 115(Pt 5):1027-1039.
160. Lehmann DM, Galloway CA, Sowden MP et al. Metabolic regulation of apoB mRNA editing is associated with phosphorylation of APOBEC-1 complementation factor. Nucleic Acids Res 2006; 34:3299-3308.
161. Mild MC, Watt IN, Lu M et al. Mice deficient in APOBEC2 and APOBEC3. Mol Cell Biol 2005; 25:7270-7277.
162. Minegishi Y, Lavoie A, Cunningham-Rundles C et al Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin Immunol 2000; 97:203-210.
163. Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 2002; 418:99-103.
164. Pham P, Branstcitter R, Petruska J et al Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 2003; 424:103-107.
165. Langlois MA, Beale RC, Conticello SG et al. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res 2005; 33:1913-1923.
166. Liddament MT, Brown WL, Schumacher AJ et al. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 2004; 14:1385-1391.
167. Wiegand HL, Doehle BP, Bogerd HP et al. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO 2004; 23:2451-2458.
168. Chelico L, Sacho EJ, Erie DA et al. A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. J Biol Chem 2008; 283:13780-13791.
169. Lau PP, Xiong WJ, Zhu HJ et al. Apolipoprotein B mRNA editing is an intranuclear event that occurs posttranscriptionally coincident with splicing and polyadenylation. J Biol Chem 1991; 266:20550-20554.
170. Giangreco A, Sowden MP, Mikityansky I et al Ethanol stimulates apolipoprotein B mRNA editing in the absence of de novo RNA or protein synthesis. Biochem Biophys Res Commun 2001; 289:1162-1167.
171. Yang Y, Smith HC. Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing. Proc Natl Acad Sci USA 1997; 94:13075-13080.
172. Blanc V, Kennedy S, Davidson NO. A novel nuclear localization signal in the auxiliary domain of apobec-1 complementation factor regulates nudeocytoplasmic import and shuttling. J Biol Chem 2003; 278:41198-41204.
173. Chester A, Somasekaram A, Tzimina M et al The apolipoprotein B mRNA editing complex performs a multifunctional cycle and suppresses nonsense-mediated decay. EMBO J 2003; 22:3971-3982.
174. Lehmann DM, Galloway CA, Macclrcvey C et al. Functional characterization of APOBEC-1 complementation factor phosphorylation sites. Biochim Biophys Acta 2007; 1773:408-418.
175. Sowden MP, Lehmann DM, Lin X et al Identification of novel alternative splice variants of apobcc-1 complementation factor with different capacities to support ApoB mRNA editing. J Biol Chem 2004; 278:197-206.
176. Harris SG, Smith HC. In vitro apolipoprotein B mRNA editing activity can be modulated by fasting and refeeding rats with a high carbohydrate diet. Biochem Biophys Res Commun 1992; 183:899-903.
177. Ito S, Nagaoka H, Shinkura R et al. Activation-induced cytidinc deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proc Natl Acad Sci USA 2004; 101:1975-1980.
178. McBride KM, Barreto V, Ramiro AR et al Somatic hypermutation is limited by CRMl-dependcnt nuclear export of activation-induced deaminase. J Exp Med 2004; 199:1235-1244.
179. Basu U, Chaudhuri J, Alpert C et al The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. Nature 2005; 438(7067):508-511.
180. Chatterji M, Unniraman S, McBride KM et al. Role of activation-induced deaminase protein kinase A phosphorylation sites in Ig gene conversion and somatic hypermutation. J Immunol 2007; 179:5274-5280.
181. Chaudhuri J, Khuong C, Alt FW. Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. Nature 2004; 430:992-998.
182. Duquette ML, Pham P, Goodman MF et al. AID binds to transcription-induced structures in c-MYC that map to regions associated with translocation and hypermutation. Oncogene 2005; 24:5791-5798.
183. Ramiro AR, Stavropoulos P, Jankovic M et al. Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontcmplate strand. Nat Immunol 2003; 4:452-456.
184. Shen HM, Storb U. Activation-induced cytidine deaminase (AID) can target both DNA strands when the DNA is supercoiled. Proc Natl Acad Sci USA 2004; 101:12997-13002.
185. Mehta AaD DM. Identification of domains in APOBEC-1 complementation factor required for RNA binding and apolipoprotein B mRNA editing. RNA 2002; 8:69-82.
186. Blanc V, Henderson JO, Kennedy S et al. Mutagenesis of apobcc-1 complementation factor (ACF) reveals distinct domains that modulate RNA binding, protein-protein interaction with apobec-1 and complementation of C to U RNA editing activity. J Biol Chem 2001; 276:46386-93.
187. Chen X, Sparks JD, Yao Z et al. Hepatic polysomes that contain apoprotein B mRNA have unusual physical properties. J Biol Chem 1993; 268:21007-21013.
188. Sparks JD, Sparks CE. Insulin modulation of hepatic synthesis and secretion of apoB by rat hepatocytes. J Biol Chem 1990; 265:8854-8862.
189. Siddiqui JF, Van Mater D, Sowden MP et al Disproportionate relationship between APOBEC-1 expression and apolipoprotein B mRNA editing activity. Exp Cell Res 1999; 252:154-164.
190. Sowden M, Hamm JK, Smith HC. Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing. J Biol Chem 1996; 271:3011-3017.
191. Yamanaka S, Balestra ME, Ferrell LD et al Apolipoprotein B mRNA-edicing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA 1995; 92:8483-8487.
192. Yamanaka S, Poksay KS, Arnold KS et al. A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA- editing enzyme. Genes Dev 1997; 11:321-333.
193. Yamanaka S, Poksay KS, Driscoll DM et al Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif. J Biol Chem1996; 271:11506-11510.
194. Babbage G, Ottcnsmeier CH, Blaydes J et al Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. Cancer Res 2006; 66:3996-4000.
195. Okazaki IM, Hiai H, Kakazu N et al Constitutive expression of AID leads to tumorigenesis. J Exp Med 2003; 197:1173-1181.
196. Oppczzo P, Vuillier F, Vasconcelos Y et al. Chronic lymphocytic leukemia B-cclls expressing AID display dissociation between class switch recombination and somatic hypermutation. Blood 2003; 101:4029-4032.
197. Ramiro AR, Jankovic M, Eisenreich T et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 2004; 118:431-438.
198. Ramiro AR, Jankovic M, Callen E et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006; 440:105-109.
199. Dochle BP, Schafer A, Cullen BR. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 2005; 339:281-288.
200. Nagaoka H, Ito S, Muramatsu M et al. DNA cleavage in immunoglobulin somatic hypermutation depends on dc novo protein synthesis but not on uracil DNA glycosylase. Proc Natl Acad Sci USA 2005; 102:2022-2027.
201. Endo Y, Marusawa H, Kinoshita K et al. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 2007; 26:5587-5595
202. Aoufouchi S, Faili A, Zober C et al. Proteasomal degradation restricts the nuclear lifespan of AID. J Exp Med 2008; 205:1357-1368.
203. Xie K, Sowden MP, Dance GS et al. The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1. Proc Natl Acad Sci USA2004; 101:8114-8119.
204. Muto T, Muramatsu M, Taniwaki M et al. Isolation, tissue distribution and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene. Genomics 2000; 68:85-88.
205. Bennett RP, Diner E, Sowden MP et al. APOBEC-1 and AID are nucleo-cytoplasmic trafficking proteins but APOBEC3G cannot traffic. Biochem Biophys Res Commun 2006; 350:214-219.
206. Bennett RP, Prcsnyak V, Wedekind JE et al. Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding. J Biol Chem 2008; 283:7320-7327.
207. Huang J, Liang Z, Yang B et al. Derepression of microRNA-mcdiatcd protein translation inhibition by apolipoprotcin B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members. J Biol Chem 2007; 282:33632-33640.
208. Kozak SL, Marin M, Rose KM et al. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J Biol Chem 2006; 281:29105-29119.
209. Gallois-Montbrun S, Holmes RK, Swanson CM et al. Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol 2008; 82:5636-5642.
210. Stopak KS, Chiu YL, Kropp J et al. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem 2006; 282:3539-3546.
211. Wichroski MJ, Robb GB, Rana TM. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog 2006; 2(5):e41.
212. Wichroski MJ, Ichiyama K, Rana TM. Analysis of HIV-1 viral infectivity factor-mediated proteasomc-de-pendent depletion of APOBEC3G: correlating function and subcellular localization. J Biol Chem 2005; 280:8387-8396.
213. Gallois-Montbrun S, Kramer B, Swanson CM et al Antiviral protein APOBEC3G localizes to ribonu-clcoprotein complexes found in P bodies and stress granules. J Virol 2007; 81:2165-2178.
214. Khan MA, Goila-Gaur R, Opi S et al. Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 2007; 4:48.
215. Bach D, Peddi S, Mangeat B et al Characterization of APOBEC3G binding to 7SL RNA. Retrovirology2008; 5(1):54.
216. Wang T, Zhang W, Tian C et al. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology 2008; 377:71-79
217. Chiu YL, Soros VB, Kreisberg JF et al Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T-cells. Nature 2005; 435:108-114.
218. Kreisberg JF, Yonemoto W, Greene WC. Endogenous factors enhance HIV infection of tissue naive CD4 T-cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med 2006; 203:865-870.
219. Soros VB, Yonemoto W, Greene WC. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA and subsequently activated by RNase H. PLoS Pathog 2007; 3(2):e15.
220. Muckenfuss H, Kaiser JK, Krebil E et al. Spl and Sp3 regulate basal transcription of the human APOBEC3G gene. Nucleic Acids Res 2007; 35:3784-3796.
221. Rose KM, Marin M, Kozak SL et al. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J Biol Chem 2004; 279:41744-41749.
222. Dang Y, Siew LM, Zheng YH. APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated. J Biol Chcm 2008; 283:13124-13131.
223. Mehlc A, Strack B, Aneuta P et al Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitm-proteasome pathway. J Biol Chem 2004; 279:7792-7798.
224. Shechy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasomc in response to HIV-1 Vif. Nat Med 2003; 9:1404-1407.
225. Liu B, Yu X, Luo K et al Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 2004; 78:2072-2081.
226. Stopak K, De Noronha C, Yonemoto W et al HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing both Its Translation and Intracellular Stability. Mol Cell 2003; 12:591-601.
227. Conticcllo SG, Harris RS, Neuberger MS. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 2003; 13:2009-2013.
228. Tian C, Yu X, Zhang W et al Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 2006; 80:3112-3115.
229. Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 2007; 81:8201-8210.
230. Yamashita T, Kamada K, Hatcho K et al Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect 2008; Epub Ahead of Print.
231. Mehlc A, Wilson H, Zhang C et al Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol 2007; 81:13235-13241.
232. He Z, Zhang W, Chen G, Xu R et al Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol 2008; In press.
233. Kobayashi M, Takaori-Kondo A, Miyauchi Y et al. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cull-in5-Elongin B-Elongin C complex is essential for Vif function. J Biol Chem 2005; 280:18573-18578.
234. Mehle A, Goncalves J, Sama-Marta M et al Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 2004; 18:2861-2866.
235. Stanley BJ, Ehrlich ES, Short L et al Structural insight into the HIV Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol 2008; In press.
236. Yu X, Yu Y, Liu B et al Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003; 302:1056-1060.
237. Yu Y, Xiao Z, Ehrlich ES et al Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 2004; 18:2867-2872.
238. Bogerd HP, Dochlc BP, Wiegand HL et al. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 2004; 101:3770-3774.
239. Huthoff H, Malim MH. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol 2007; 81:3807-3815.
240. Xu H, Svarovskaia ES, Barr R et al A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA 2004; 101:5652-5657.
241. Santa-Marta M, da Silva FA, Fonseca AM et al. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Biol Chem 2005; 280:8765-8775.
242. Mangeat B, Turelli P, Liao S et al A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 2004; 279:14481-14483.
243. Zhang L, Saadatmand J, Li X et al Function analysis of sequences in human APOBEC3G involved in Vif-mcdiated degradation. Virology 2008; 370:113-121.
244. Alce TM, Popik W. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 2004; 279:34083-34086.
245. Cen S, Guo F, Niu M et al The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 2004; 279:33177-33184.
246. Schafer A, Bogerd HP, Cullen BR. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 2004; 328:163-168.
247. Xu H, Chertova E, Chen J et al. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 2007; 360:247-256.
248. Zennou V, Perez-Caballero D, Gottlinger H et al APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol 2004; 78:12058-12061.
249. Lau PP, Zhu H-J, Baldini HA et al Dimeric structure of a human apo B mRNA editing protein and cloning and chromosomal localization of its gene. Proc Natl Acad Sci USA 1994; 91:8522-8526.
250. Oka K, Kobayashi K, Sullivan M et al. Tissue-specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus-mediated transfer of a dominant negative mutant APOBEC-1 leads to increased low density lipoprotein in mice. J Biol Chem 1997; 272:1456-1460.
251. Yang Y, Smith HC. In vitro reconstitution of apolipoprotein B RNA editing activity from recombinant APOBEC-1 and McArdle cell extracts. Biochem Biophys Res Commun 1996; 218:797-801.
252. Chen KM, Martemyanova N, Lu Y et al Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G. FEBS Lett 2007; 581:4761-4766.
253. Chen KM, Harjes E, Gross PJ et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 2008; 452:116-119.
254. Wang J, Shinkura R, Muramatsu M et al. Identification of a specific domain required for dimerization of activation-induced cytidine deaminase. J Biol Chem 2006; 281:19115-19123.
255. Prochnow C, Bransteitter R, Klein MG et al. The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 2007; 445:447-451.
256. Brar SS, Sacho EJ, Tessmer I et al. Activation-induced deaminase, AID, is catalytically active as a monomer on single-stranded DNA. DNA Repair (Amst) 2008; 7:77-87.
257. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC and intrinsic immunity. Retrovirology 2008; 5:51.